Gynecologic Cancers | Oncology Grand Rounds Series: Part 5 — Gynecologic Cancers (Webinar Proceedings) - a podcast by Dr Neil Love
from 2020-09-23T13:19:56
::
::
Proceedings from the fifth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Paula J Anastasia, Ms Jennifer Filipi, Dr David M O’Malley and Dr Shannon N Westin.
- Introduction (00:00)
- Mechanism of action of PARP inhibitors and integration into the therapeutic algorithm for patients with advanced ovarian cancer (OC) (5:16)
- Efficacy and duration of maintenance therapy with olaparib or niraparib in the Phase III SOLO-1 and PRIMA trials for patients with OC in the first-line setting (13:01)
- Response and tolerability with olaparib as maintenance therapy for patients with advanced OC with BRCA mutations (20:05)
- Genetic testing for patients with OC; selection of PARP inhibitor therapy (25:01)
- Choice of PARP inhibitor alone or in combination with bevacizumab as maintenance therapy for patients with advanced OC (29:17)
- Activity of olaparib as maintenance therapy for OC; gastrointestinal and hematologic toxicities with PARP inhibitors (34:49)
- Role of immune checkpoint inhibitors in the treatment of endometrial cancer; significance of microsatellite instability (47:37)
- Emerging data with pembrolizumab alone or in combination with lenvatinib for endometrial cancer (54:48)
- Dosing considerations and side effects with pembrolizumab/lenvatinib (59:12)
- Response to immune checkpoint inhibitors in patients with cervical cancer (1:09:21)
- Immune-related adverse events associated with checkpoint inhibitors; considerations for the use of immune checkpoint inhibitors in the COVID-19 era (1:14:34)
CNE information and select publications
Further episodes of Research To Practice | Oncology Videos
Further podcasts by Dr Neil Love
Website of Dr Neil Love